{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:06:59Z","timestamp":1759666019075,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA112403"],"award-info":[{"award-number":["CA112403"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP120732-P5","RP150197"],"award-info":[{"award-number":["RP120732-P5","RP150197"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572619"],"award-info":[{"award-number":["81572619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13058-018-1024-9","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T12:30:39Z","timestamp":1534336239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells"],"prefix":"10.1186","volume":"20","author":[{"given":"Mao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonglin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-9162","authenticated-orcid":false,"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"issue":"2","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1024_CR2","volume-title":"Cancer of the breast","author":"WL Donegan","year":"2002","unstructured":"Donegan WL, Spratt JS. Cancer of the breast, vol. 5. Philadelphia: Saunders; 2002."},{"issue":"20","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","volume":"94","author":"VL Ernster","year":"2002","unstructured":"Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1024_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135\u201344.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1024_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1006461422273","volume":"65","author":"SJ Santner","year":"2001","unstructured":"Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 2001;65(2):101\u201310.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1024_CR6","first-page":"313","volume":"148","author":"PJ Dawson","year":"1996","unstructured":"Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148(1):313\u20139.","journal-title":"Am J Pathol"},{"issue":"21","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/jnci\/85.21.1725","volume":"85","author":"FR Miller","year":"1993","unstructured":"Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst. 1993;85(21):1725\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"1024_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/jnci\/92.14.1185a","volume":"92","author":"FR Miller","year":"2000","unstructured":"Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92(14):1185\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/bcr2358","volume":"11","author":"F Behbod","year":"2009","unstructured":"Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11(5):R66.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1024_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in Cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259\u201367.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1024_CR12","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1158\/1078-0432.CCR-17-1232","volume":"23","author":"L Formisano","year":"2017","unstructured":"Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, et al. Association of FGFR1 with ERalpha maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER(+) breast Cancer. Clin Cancer Res. 2017;23(20):6138\u201350.","journal-title":"Clin Cancer Res"},{"issue":"45","key":"1024_CR13","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/onc.2010.333","volume":"29","author":"H Aguilar","year":"2010","unstructured":"Aguilar H, Sole X, Bonifaci N, Serra-Musach J, Islam A, Lopez-Bigas N, Mendez-Pertuz M, Beijersbergen RL, Lazaro C, Urruticoechea A, et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene. 2010;29(45):6071\u201383.","journal-title":"Oncogene"},{"issue":"50","key":"1024_CR14","doi-asserted-by":"publisher","first-page":"83424","DOI":"10.18632\/oncotarget.13117","volume":"7","author":"WS Brown","year":"2016","unstructured":"Brown WS, Akhand SS, Wendt MK. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. Oncotarget. 2016;7(50):83424\u201336.","journal-title":"Oncotarget"},{"issue":"2","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jb\/mvq121","volume":"149","author":"N Itoh","year":"2011","unstructured":"Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149(2):121\u201330.","journal-title":"J Biochem"},{"issue":"3","key":"1024_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013;14(3):166\u201380.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semcdb.2015.12.014","volume":"53","author":"X Li","year":"2016","unstructured":"Li X, Wang C, Xiao J, McKeehan WL, Wang F. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol. 2016;53:155\u201367.","journal-title":"Semin Cell Dev Biol"},{"issue":"5103","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.8456318","volume":"259","author":"M Kan","year":"1993","unstructured":"Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science. 1993;259(5103):1918\u201321.","journal-title":"Science"},{"issue":"3","key":"1024_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215\u201366.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"7","key":"1024_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1101\/gad.277137.115","volume":"30","author":"JR Brewer","year":"2016","unstructured":"Brewer JR, Mazot P, Soriano P. Genetic insights into the mechanisms of Fgf signaling. Genes Dev. 2016;30(7):751\u201371.","journal-title":"Genes Dev"},{"issue":"3","key":"1024_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/(SICI)1097-4652(199812)177:3<411::AID-JCP5>3.0.CO;2-Y","volume":"177","author":"R Wieder","year":"1998","unstructured":"Wieder R, Fenig E, Wang H, Wang Q, Paglin S, Menzel T, Gabrilove J, Fuks Z, Yahalom J. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. J Cell Physiol. 1998;177(3):411\u201325.","journal-title":"J Cell Physiol"},{"issue":"11","key":"1024_CR22","doi-asserted-by":"publisher","first-page":"e49970","DOI":"10.1371\/journal.pone.0049970","volume":"7","author":"KM Tarkkonen","year":"2012","unstructured":"Tarkkonen KM, Nilsson EM, Kahkonen TE, Dey JH, Heikkila JE, Tuomela JM, Liu Q, Hynes NE, Harkonen PL. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One. 2012;7(11):e49970.","journal-title":"PLoS One"},{"issue":"6","key":"1024_CR23","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-08-3398","volume":"69","author":"W Xian","year":"2009","unstructured":"Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM, Brugge JS. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009;69(6):2244\u201351.","journal-title":"Cancer Res"},{"issue":"12","key":"1024_CR24","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1158\/0008-5472.CAN-09-4404","volume":"70","author":"AC Pond","year":"2010","unstructured":"Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, et al. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010;70(12):4868\u201379.","journal-title":"Cancer Res"},{"issue":"6","key":"1024_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccr.2007.11.004","volume":"12","author":"VD Acevedo","year":"2007","unstructured":"Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559\u201371.","journal-title":"Cancer Cell"},{"issue":"5","key":"1024_CR26","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085\u201394.","journal-title":"Cancer Res"},{"issue":"9","key":"1024_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/onc.2014.51","volume":"34","author":"B Kim","year":"2015","unstructured":"Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, et al. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to met-targeted therapy. Oncogene. 2015;34(9):1083\u201393.","journal-title":"Oncogene"},{"issue":"3","key":"1024_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.apsb.2014.02.003","volume":"4","author":"N Anreddy","year":"2014","unstructured":"Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JN, Chen ZS. PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm Sin B. 2014;4(3):202\u20137.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"1024_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1541-7786.MCR-12-0652","volume":"11","author":"H Terai","year":"2013","unstructured":"Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013;11(7):759\u201367.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"1024_CR30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1541-7786.MCR-13-0358","volume":"11","author":"R Gyanchandani","year":"2013","unstructured":"Gyanchandani R, Ortega Alves MV, Myers JN, Kim S. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol Cancer Res. 2013;11(12):1585\u201396.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1024_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/1535-7163.MCT-17-0367","volume":"17","author":"WM Lau","year":"2018","unstructured":"Lau WM, Teng E, Huang KK, Tan JW, Das K, Zang Z, Chia T, Teh M, Kono K, Yong WP, et al. Acquired resistance to FGFR inhibitor in diffuse-type gastric Cancer through an AKT-independent PKC-mediated phosphorylation of GSK3beta. Mol Cancer Ther. 2018;17(1):232\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1024_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","volume":"16","author":"J Datta","year":"2017","unstructured":"Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, et al. Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398. Mol Cancer Ther. 2017;16(4):614\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1024_CR33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/ijc.30848","volume":"141","author":"JK Cowell","year":"2017","unstructured":"Cowell JK, Qin H, Hu T, Wu Q, Bhole A, Ren M. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia\/lymphomas. Int J Cancer. 2017;141(9):1822\u20139.","journal-title":"Int J Cancer"},{"issue":"18","key":"1024_CR34","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-17-0478","volume":"23","author":"F Malchers","year":"2017","unstructured":"Malchers F, Ercanoglu M, Schutte D, Castiglione R, Tischler V, Michels S, Dahmen I, Bragelmann J, Menon R, Heuckmann JM, et al. Mechanisms of primary drug resistance in FGFR1-amplified lung Cancer. Clin Cancer Res. 2017;23(18):5527\u201336.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1024_CR35","first-page":"8256","volume":"63","author":"KW Freeman","year":"2003","unstructured":"Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003;63(23):8256\u201363.","journal-title":"Cancer Res"},{"issue":"19","key":"1024_CR36","first-page":"6237","volume":"63","author":"KW Freeman","year":"2003","unstructured":"Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003;63(19):6237\u201343.","journal-title":"Cancer Res"},{"issue":"11","key":"1024_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nri3313","volume":"12","author":"A Ma","year":"2012","unstructured":"Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012;12(11):774\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1024_CR38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.bbrc.2017.04.144","volume":"487","author":"Q Jia","year":"2017","unstructured":"Jia Q, Sun H, Xiao F, Sai Y, Li Q, Zhang X, Yang S, Wang H, Yang Y, Wu CT, et al. miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting A20 and activation of NF-kappaB signaling. Biochem Biophys Res Commun. 2017;487(4):868\u201374.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1024_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4149\/neo_2017_309","volume":"64","author":"T Huang","year":"2017","unstructured":"Huang T, Yin L, Wu J, Gu JJ, Ding K, Zhang N, Du MY, Qian LX, Lu ZW, He X. TNFAIP3 inhibits migration and invasion in nasopharyngeal carcinoma by suppressing epithelial mesenchymal transition. Neoplasma. 2017;64(3):389\u201394.","journal-title":"Neoplasma"},{"key":"1024_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-015-0454-6","volume":"14","author":"H Chen","year":"2015","unstructured":"Chen H, Hu L, Luo Z, Zhang J, Zhang C, Qiu B, Dong L, Tan Y, Ding J, Tang S, et al. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression. Mol Cancer. 2015;14:186.","journal-title":"Mol Cancer"},{"issue":"32","key":"1024_CR41","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1038\/sj.onc.1210269","volume":"26","author":"JA Vendrell","year":"2007","unstructured":"Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20\/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene. 2007;26(32):4656\u201367.","journal-title":"Oncogene"},{"issue":"10","key":"1024_CR42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ncb3609","volume":"19","author":"JH Lee","year":"2017","unstructured":"Lee JH, Jung SM, Yang KM, Bae E, Ahn SG, Park JS, Seo D, Kim M, Ha J, Lee J, et al. A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. Nat Cell Biol. 2017;19(10):1260\u201373.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"1024_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2015.267","volume":"30","author":"Y Saitoh","year":"2016","unstructured":"Saitoh Y, Hamano A, Mochida K, Kakeya A, Uno M, Tsuruyama E, Ichikawa H, Tokunaga F, Utsunomiya A, Watanabe T, et al. A20 targets caspase-8 and FADD to protect HTLV-I-infected cells. Leukemia. 2016;30(3):716\u201327.","journal-title":"Leukemia"},{"issue":"10","key":"1024_CR44","doi-asserted-by":"publisher","first-page":"e0141165","DOI":"10.1371\/journal.pone.0141165","volume":"10","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wan M, Zhou Q, Wang H, Wang Z, Zhong X, Zhang L, Tai S, Cui Y. The prognostic role of SOCS3 and A20 in human cholangiocarcinoma. PLoS One. 2015;10(10):e0141165.","journal-title":"PLoS One"},{"issue":"3","key":"1024_CR45","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3892\/ijo.2017.3869","volume":"50","author":"YE Hadisaputri","year":"2017","unstructured":"Hadisaputri YE, Miyazaki T, Yokobori T, Sohda M, Sakai M, Ozawa D, Hara K, Honjo H, Kumakura Y, Kuwano H. TNFAIP3 overexpression is an independent factor for poor survival in esophageal squamous cell carcinoma. Int J Oncol. 2017;50(3):1002\u201310.","journal-title":"Int J Oncol"},{"issue":"1","key":"1024_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357.","journal-title":"Nat Protoc"},{"issue":"1","key":"1024_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1024_CR48","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"issue":"8","key":"1024_CR49","doi-asserted-by":"publisher","first-page":"e0181342","DOI":"10.1371\/journal.pone.0181342","volume":"12","author":"T Nakano","year":"2017","unstructured":"Nakano T, Kanai Y, Amano Y, Yoshimoto T, Matsubara D, Shibano T, Tamura T, Oguni S, Katashiba S, Ito T, et al. Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures. PLoS One. 2017;12(8):e0181342.","journal-title":"PLoS One"},{"issue":"1","key":"1024_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.it.2013.10.005","volume":"35","author":"L Catrysse","year":"2014","unstructured":"Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014;35(1):22\u201331.","journal-title":"Trends Immunol"},{"issue":"11","key":"1024_CR51","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","volume":"10","author":"G Zhao","year":"2011","unstructured":"Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10(11):2200\u201310.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1024_CR52","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045\u201356.","journal-title":"Cancer Res"},{"key":"1024_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fcell.2016.00053","volume":"4","author":"R Busca","year":"2016","unstructured":"Busca R, Pouyssegur J, Lenormand P. ERK1 and ERK2 map kinases: specific roles or functional redundancy? Front Cell Dev Biol. 2016;4:53.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"1024_CR54","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1083\/jcb.200107119","volume":"157","author":"BE Welm","year":"2002","unstructured":"Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol. 2002;157(4):703\u201314.","journal-title":"J Cell Biol"},{"issue":"10","key":"1024_CR55","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457\u201367.","journal-title":"Cancer Res"},{"issue":"2","key":"1024_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ccr.2014.01.005","volume":"25","author":"E Grabocka","year":"2014","unstructured":"Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell. 2014;25(2):243\u201356.","journal-title":"Cancer Cell"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1024-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:40:22Z","timestamp":1589550022000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1024-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"22 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocols for animal experiments were approved by the Institutional Animal Care and Use Committee of Southwest Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"97"}}